The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Efficacy of Tremacamra, a Soluble Intercellular Adhesion Molecule 1, for Experimental Rhinovirus Infection: A Randomized Clinical Trial
Abstract
CONTEXT: Attachment of most rhinovirus subtypes to cells depends on a cellular receptor, the intercellular adhesion molecule 1 (ICAM-1). A recombinant soluble ICAM-1 (tremacamra, formerly BIRR 4) has shown possible efficacy in early studies. OBJECTIVE: To determine the efficacy and safety of intranasal administration of tremacamra in experimental rhinovirus colds in humans. DESIGN: Four randomized, double-blind, placebo-controlled trials conducted in January to March 1996. SETTING AND SUBJECTS: Volunteers between the ages of 18 and 60 years who had an antibody titer of 1:4 or less to the challenge virus. Subjects were isolated in a hotel room during study days 0 to 8; symptoms were recorded through day 14. A total of 198 subjects were randomized, of whom 196 received drug or placebo and were included in the safety analysis. A total of 177 subjects were included in the efficacy analysis. INTERVENTIONS: Tremacamra or placebo was given beginning 7 hours before inoculation with rhinovirus type 39 (preinoculation studies) or 12 hours after (postinoculation studies). Tremacamra as an inhaled solution or as a powder (each given preinoculation and postinoculation for a total of 4 studies) and placebo were given in 6 doses at 3-hour intervals daily during days 1 through 7. Recipients of active treatment received 367 microg of tremacamra per nostril per dose for a total of 4.4 mg/d. MAIN OUTCOME MEASURES: Effect of tremacamra on infection, as determined by virus isolation and seroconversion, and on illness, as determined by symptom scores, clinical colds, and nasal mucus weights. Treatment-by-study interaction was not significant, so results were pooled for the main analysis. RESULTS: A total of 88 (92%) of the 96 subjects in the placebo groups and 69 (85%) of the 81 subjects in the active treatment groups were infected (P=.19). For placebo vs tremacamra, respectively, the total symptom score (+/- 95% confidence interval [CI]) was 17.6 (+/- 2.7) vs 9.6 (+/- 2.9), the proportion of clinical colds was 64/96 (67% +/- 9%) vs 36/81 (44% +/- 11%), and the nasal mucus weight was 32.9 (+/- 8.8) g vs 14.5 (+/- 9.4) g (P<.001 for all comparisons). Tremacamra was not associated with adverse effects or evidence of absorption through the nasal mucosa and did not interfere with development of neutralizing antibody. CONCLUSION: Tremacamra reduced the severity of experimental rhinovirus colds. Whether tremacamra will be useful clinically will require further study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A cell adhesion molecule, ICAM-1, is the major surface receptor for rhinoviruses
Staunton, D. E., Merluzzi, V. J., Rothlein, R., Barton, R., Marlin, S. D., & Springer, T. A. (1989) · Cell · doi:10.1016/0092-8674(89)90689-2 · Cited by 821 · cited 4×
“JAMA, May 19, 1999—Vol 281, No. 19 1799 Downloaded From: https://jamanetwork.com/ on 06/09/2022 natural circulating ICAM-1.”
BackgroundInfluentialZhu, Z., Tang, W., Ray, A., Wu, Y., Einarsson, O., Landry, M. L., Gwaltney, J., & Elias, J. A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118431 · Cited by 282
Douglas, R. M., Moore, B. W., Miles, H. B., Davies, L. M., Graham, N. M. H., Ryan, P., Worswick, D. A., & Albrecht, J. K. (1986) · New England Journal of Medicine · doi:10.1056/nejm198601093140201 · Cited by 167
Turner, R. B., Weingand, K. W., Yeh, C., & Leedy, D. W. (1998) · Clinical Infectious Diseases · doi:10.1086/513922 · Cited by 165
Self-citationIncubation periods of experimental rhinovirus infection and illness
Harris, J. M., & Gwaltney, J. M. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/23.6.1287 · Cited by 73 · cited 1×
“A previous study in volunteers challenged with rhinovirus type 39 found that most subjects have evidence for 1 cycle of virus replication by 12 hours after virus challenge.(34) The efficacy of tremacamra on rhinovirus-induced illness was similar when the medication was given either 7 hours prior to virus challenge or…”
Method
Cited by
Heikkinen, T., & Järvinen, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12162-9 · Cited by 1,067
Jacobs, S. E., Lamson, D. M., St. George, K., & Walsh, T. J. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00077-12 · Cited by 704
The life cycle of non-polio enteroviruses and how to target it
Baggen, J., Thibaut, H. J., Strating, J. R. P. M., & van Kuppeveld, F. J. M. (2018) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0005-4 · Cited by 478
Bochkov, Y. A., Watters, K., Ashraf, S., Griggs, T. F., Devries, M. K., Jackson, D. J., Palmenberg, A. C., & Gern, J. E. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421178112 · Cited by 422
The role of viruses in acute exacerbations of asthma
Jackson, D. J., & Johnston, S. L. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.04.021 · Cited by 351
“It has not been tested as a therapy for asthma exacerbations, and the requirement for 6 times daily treatment along with the fact that it was only really effective if used within 12 hours of infection led to its development being halted.(117) A long-acting neutralizing antibody (akin to palivizumab for RSV) would like…”
Background
Metadata
- Authors
- Turner, R. B., Wecker, M. T., Pohl, G., Witek, T. J., McNally, E., St. George, R., Winther, B., & Hayden, F. G.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 1999-05-19
- Volume
- 281
- Issue
- 19
- Pages
- 1797
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2063193862
- Cited by
- 206
- References
- 5
- FWCI
- 9.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.